{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:13:20Z","timestamp":1790201600089,"version":"4.1.0"},"reference-count":72,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Neurol Disord"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:p>The development of novel therapy classes such as Bruton\u2019s tyrosine kinase (BTK) inhibitors, which target disability progression independent of relapses and largely independent of new lesion formation, requires a reappraisal of strategies in the treatment of multiple sclerosis (MS). We argue that this novel class of treatment further emphasizes the need for early and aggressive treatment with classical disease-modifying compounds for the prevention of both relapses and new MRI lesion formation and their associated disability accrual. This will extend the window to recognize early progressive disability accumulation independent of acute focal inflammatory activity, and for people with MS to benefit from novel therapies such as BTK inhibition, which target damaging pathophysiological processes independent of peripherally driven focal inflammation.<\/jats:p>","DOI":"10.1177\/17562864251359002","type":"journal-article","created":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:58:02Z","timestamp":1758362282000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Aggressive treatment of early acute focal inflammatory activity to extend the window for BTK inhibition in multiple sclerosis"],"prefix":"10.1177","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9766-8661","authenticated-orcid":false,"given":"Joost","family":"Smolders","sequence":"first","affiliation":[{"name":"Department of Neurology, MS Center ErasMS, Erasmus MC, University Medical Center Rotterdam, Dr. Molewaterplein 40, 3015GD Rotterdam, The Netherlands"},{"name":"Department of Immunology, MS Center ErasMS, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands"},{"name":"Neuroimmunology Research Group, Netherlands Institute for Neuroscience, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8174-2898","authenticated-orcid":false,"given":"Ide","family":"Smets","sequence":"additional","affiliation":[{"name":"Department of Neurology, MS Center ErasMS, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2616-8464","authenticated-orcid":false,"given":"Beatrijs","family":"Wokke","sequence":"additional","affiliation":[{"name":"Department of Neurology, MS Center ErasMS, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,9,20]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-018-0082-z"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00289-7"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1177\/17562864241233041"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2415985"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2415988"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awq076"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awq118"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2016.03.011"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002830"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-510X(99)00143-4"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awm329"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000341935.41852.82"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awv105"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.61.2.217"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181feb26f"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awz156"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcae395"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70103-0"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03625-7"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909494"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044397"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601277"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917246"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0902533"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61768-1"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-024-01050-x"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15862"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181e3973f"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2017.00577"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2021.1886082"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.799138"},{"issue":"1","key":"e_1_3_4_33_2","first-page":"39","article-title":"Treating early relapsing multiple sclerosis: induction & escalation approaches","volume":"22","author":"Bou Rjeily N","year":"2022","unstructured":"Bou Rjeily N, Mowry E. Treating early relapsing multiple sclerosis: induction & escalation approaches. Pract Neurol 2022; 22(1): 39\u201343.","journal-title":"Pract Neurol"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585241258692"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000560"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awg081"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2013-304951"},{"key":"e_1_3_4_38_2","article-title":"Prognostic factors for long-term outcomes in relapsing\u2013remitting multiple sclerosis","volume":"2","author":"Traboulsee AL","year":"2016","unstructured":"Traboulsee AL, Cornelisse P, Sandberg-Wollheim M, et al. Prognostic factors for long-term outcomes in relapsing\u2013remitting multiple sclerosis. Mult Scler J Exp Transl Clin 2016; 2: 2055217316666406.","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1277477"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606468"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30475-6"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.1568"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.4655"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2025.0495"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209444"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00328-4"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458518814117"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70308-9"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2201904"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.0405"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.160909"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54430-8"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-024-00468-4"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14705"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2024.4164"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00154-0"},{"key":"e_1_3_4_57_2","volume-title":"LB1.1. Paramagnetic rim lesions as a prognostic and predictive biomarker in the tolebrutinib phase 3 trials for disability outcomes","author":"Oh J","unstructured":"Oh J, Fox RJ, Arnold DL, et al. LB1.1. Paramagnetic rim lesions as a prognostic and predictive biomarker in the tolebrutinib phase 3 trials for disability outcomes. Presented at ACTRIMS 2025, February 27\u2013March 1, 2025, West Palm Beach, Florida."},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200253"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585221141964"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200133"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51969"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200052"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.70052"},{"key":"e_1_3_4_64_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-018-1818-y"},{"key":"e_1_3_4_65_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06250-x"},{"key":"e_1_3_4_66_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.27144"},{"key":"e_1_3_4_67_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26807"},{"key":"e_1_3_4_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2025.112430"},{"key":"e_1_3_4_69_2","volume-title":"Revised McDonald criteria 2023","author":"Montalban X.","unstructured":"Montalban X. Revised McDonald criteria 2023. Presented at Scientific Session 1, ECTRIMS 2024, 18\u201320 September 2024, Copenhagen, Denmark."},{"key":"e_1_3_4_70_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585221109386"},{"key":"e_1_3_4_71_2","doi-asserted-by":"publisher","DOI":"10.1177\/17562864231211077"},{"issue":"12","key":"e_1_3_4_72_2","first-page":"1330","article-title":"Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis","volume":"93","author":"Zhu C","year":"2022","unstructured":"Zhu C, Zhou Z, Roos I, et al. Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis. J Neurol Neurosurg Psychiatry 2022; 93(12): 1330\u20131337.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_3_4_73_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2023.1542"}],"container-title":["Therapeutic Advances in Neurological Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864251359002","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17562864251359002","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864251359002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T13:19:54Z","timestamp":1758547194000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17562864251359002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":72,"alternative-id":["10.1177\/17562864251359002"],"URL":"https:\/\/doi.org\/10.1177\/17562864251359002","relation":{},"ISSN":["1756-2864","1756-2864"],"issn-type":[{"value":"1756-2864","type":"print"},{"value":"1756-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"article-number":"17562864251359002"}}